Completed Access to Information Requests

About this information

Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).

If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.

*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.

Download datasets of the summaries of completed access to information requests.

Current Search

Report Type

Organization

Disposition

Year

Month

Found 4247 record(s)

Req # A-2023-001157

Records detailing costs associated with personal drivers for your executive team. Include staffing costs for any drivers on-staff, or the costs of hiring them on a as-needed basis. Also include details for any vehicles purchased, or any vehicle maintenance costs. Limit time frame: 2018 and 2023.

Organization: Health Canada

6 page(s)
March 2024

Req # A-2023-001212

Any Screening Acceptance Letter sent by Health Canada to the sponsor of the Second Liraglutide Abbreviated New Drug Submission (ANDS).

Organization: Health Canada

1 page(s)
March 2024

Req # A-2023-001216

An annotated copy of the most recent Certified Product Information Document (CPID) submitted for the Second Liraglutide Abbreviated New Drug Submission (ANDS).

Organization: Health Canada

45 page(s)
March 2024

Req # A-2023-001450

Amendments to the Food and Drug Regulations (FDR) to include the specificities regarding the review of drugs and vaccines for treating COVID-19. Between November 30 and December 21, 2020, consultations took place on the Guidelines with the manufacturers of drugs to treat COVID-19, manufacturers who were planning to submit an authorization request for a drug to treat COVID-19 and the holders of drug establishment licences (DEL).

Organization: Health Canada

52 page(s)
March 2024

Req # A-2020-000006

Adverse Drug Reactions (ADRs) for IPRATROPIUM BROMIDE. Report numbers: E2B_01988611, E2B_02511637, E2B_02535417 E2B_02537844, E2B_02541907, E2B_02544792, E2B_01451565, E2B_02554415.

Organization: Health Canada

173 page(s)
March 2024

Req # A-2020-000872

Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 20-108491-380.

Organization: Health Canada

7 page(s)
March 2024

Req # A-2020-000873

Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 20-108397-469.

Organization: Health Canada

12 page(s)
March 2024

Req # A-2020-001076

Adverse Drug Reactions (ADRs) for Zenhale. Report numbers: 000687913, E2B_00037157, E2B_00282538, E2B_00356618, E2B_00785746, 000585164, 000335842, E2B_00356618, E2B_00785746. ADR for Zepatier. Report number: 000684523.

Organization: Health Canada

934 page(s)
March 2024

Req # A-2020-001078

Adverse Drug Reactions (ADRs). Report numbers: 000916615, 000916620, 000918479, E2B_03252887.

Organization: Health Canada

40 page(s)
March 2024

Req # A-2020-001136

Adverse Drug Reactions (ADRs) for FUROSEMIDE. Report numbers: 000726947, E2B_03098060.

Organization: Health Canada

15 page(s)
March 2024
Date modified: